Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) and Eisai Inc. revealed Thursday that the Federal Commission for the Protection Against Sanitary Risk (COFEPRIS) has given its approval for the chronic weight management agent VENESPRI. It would proceed ... Benzinga.com, 1 week ago
12 Stocks Moving In Thursday's Pre-Market Session - Benzinga.com, 1 week ago
Arena Pharmaceuticals (NASDAQ: ARNA ) and its marketing partner Eisai ( OTCPK:ESALY ) have announced that the anti-obesity drug Lorcaserin has been approved in Mexico . Lorcaserin is marketed as Belviq in the United States and South Korea, but will ...Seeking Alpha, 1 week ago Eisai and Arena Pharmaceuticals secure regulatory approval of VENESPRI in Mexico Pharmaceutical Business Review, 1 week ago Obesity drug Venespri (Belviq) approved in Mexico Pharma Letter, 1 week ago Eisai and Arena Pharmaceuticals Announce Regulatory Approval of VENESPRI ® (lorcaserin HCl) in Mexico Stockwatch, 1 week ago
Eisai : listed for 15th Consecutive Year FTSE4Good Index Series, an Index for Socially Responsible Investment
- (ACN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that it has been included in the FTSE4Good Index Series for the 15th consecutive year since its initial inclusion in 2002. The FTSE4Good Index Series ...4 Traders, 3 weeks ago Eisai listed for 15th Consecutive Year FTSE4Good Index Series, an Index for Socially Responsible Investment Benzinga.com, 3 weeks ago Eisai launches U.S. Fycompa oral suspension for patients with swallowing problems FiercePharma, 1 month ago Ncomputing announces MX100 3 User Thin Client Kit For Less Than 1/3 The Cost Of A PC Based Solution APN News, 1 month ago
, the U. S. Food and Drug Administration approved lenvatinib capsules (Lenvima, Eisai, Inc.), in combination with everolimus, for the treatment of advanced renal cell carcinoma following one prior anti-angiogenic therapy.Lenvatinib was first ...OncologyNurse.com, 2 weeks ago BRIEF-R&I affirms Eisais rating at "A+" and stable outlook Reuters UK, 2 weeks ago Eisai Highlights its Strong Pipeline and Innovative Approach to R&D at Company's U.S. Scientific Day WorldNetDaily, 3 weeks ago EISAI : Highlights its Strong Pipeline and Innovative Approach to R&D at Company's U.S. Scientific Day 4 Traders, 3 weeks ago
Eisai Co., Ltd. announced that its pharmaceutical sales subsidiary in Mexico, Eisai Laboratorios, S. de R.L. de C.V. has launched its in-house developed novel anticancer agent Lenvima (lenvatinib mesylate) in Mexico. Discovered at Eisai's Tsukuba ...PharmaBiz, 3 weeks ago Eisai launches cancer drug Lenvatinib in Mexico Pharmafile, 3 weeks ago Eisai Launches In-House Developed Novel Anticancer Agent Lenvima In Mexico FirstWord Pharma, 3 weeks ago
17-Feb-2012 Europe | Generics Icelandic generics group Actavis has launched Donepezil, a generic version of Eisai and Pfizer's drug Aricept, in some of Europe's biggest markets, following patent expiry in the UK and Sweden. The conventional ...Manufacturing Chemist, 2 weeks ago Unichem receives approval for donepezil hydrochloride tablets Business Standard India, 1 month ago Unichem Lab gets USFDA nod for Donepezil HCl tablets Myiris, 4 weeks ago Unichem Laboratories surges on receiving ANDA approval for Donepezil Hydrochloride Tablets Finalaya.com, 4 weeks ago
More from: , Moneycontrol.com...and 3 other sources
The head of Eisai in Europe has pledged to subsidize the cost of thyroid cancer drugPharma Letter, 1 week ago Eisai calls for immediate solution to CDF black hole CPhI.cn, 2 weeks ago Patients denied thyroid cancer drug in England pharmaphorum, 2 weeks ago Anger at exclusion of Eisai's Lenvima from Cancer Drugs Fund in England Pharma Letter, 2 weeks ago
AbbVie, Eisai Company, And Obtain Additional Approval For New Dosing Regimen Of Fully Human Anti-TNF Monoclonal Antibody Humira In Patients With Crohn's Disease
- (ACN Newswire) - AbbVie GK (Headquarters: Tokyo, President: James Feliciano, "AbbVie"), Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai"), and its subsidiary EA Pharma Co., Ltd. (Headquarters: Tokyo, CEO: Hajime Shimizu, "EA ...BioSpace, 1 month ago AbbVie, Eisai and EA Pharma receive additional approval for new Humira dosing regimen Pharmaceutical Technology, 1 month ago EISAI : AbbVie, Eisai, and EA Pharma Obtain Additional Approval for New Dosing Regimen of Fully Human Anti-TNF Monoclonal Antibody Humira in Patients with Crohn's Disease 4 Traders, 1 month ago AbbVie, Eisai, EA Pharma obtain additional approval for... Bio Spectrum Asia, 1 month ago
2 of 4 FEATURED COMPANIES Bracco Diagnostics, Inc. Eisai Co., Ltd. Eli Lilly and Company MORE I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS Study Reliability and Reporting Limitations Disclaimers Data Interpretation & Reporting ...Research and Markets, 2 weeks ago Multiple Sclerosis Pipeline Review Report of 178 Companies International Business Times, 1 week ago Global Tuberculosis Pipeline 2016 Market Report on 64 Companies International Business Times, 1 month ago
Study Data from Eisai Update Understanding of Breast Cancer (Subtypes of Triple-negative Breast Cancer Cell Lines React Differently to Eribulin...
Study Data from Eisai Update Understanding of Breast Cancer (Subtypes of Triple-negative Breast Cancer Cell Lines React Differently to Eribulin Mesylate) By a News Reporter-Staff News Editor at Women's Health Weekly -- Fresh data on Oncology are ...4 Traders, 3 weeks ago Higher Incidence and Rising Prevalence to Drive Breast Cancer Therapeutics Market to USD 12.8 Billion by 2020 - iHealthcareAnalyst, Inc. BizWire Express, 2 weeks ago Acupressure reduced fatigue in breast cancer survivors HealthMediciNet.com, 2 weeks ago Adaptive Randomization of Neratinib in Early Breast Cancer New England Journal of Medicine, 2 weeks ago
on your WebpageAdd Widget >Get your members hooked!